{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Olezarsen", "query": { "intervention": "Olezarsen" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Olezarsen&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T02:46:20.255Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07727538", "title": "A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 12, "start_date": "2026-07-31", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 4, "location_summary": "Birmingham, Alabama • San Francisco, California • Dallas, Texas + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07727538" }, { "nct_id": "NCT05552326", "title": "A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Hypertriglyceridemia" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2022-08-31", "completion_date": "2025-09-12", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552326" }, { "nct_id": "NCT04568434", "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2020-11-18", "completion_date": "2023-10-17", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 17, "location_summary": "Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04568434" }, { "nct_id": "NCT05079919", "title": "A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Hypertriglyceridemia" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 617, "start_date": "2021-10-25", "completion_date": "2025-07-08", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05079919" }, { "nct_id": "NCT06360237", "title": "Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 1, "location_summary": "Carlsbad, California", "locations": [ { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06360237" }, { "nct_id": "NCT05130450", "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-11-18", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 7, "location_summary": "Huntington Beach, California • Boca Raton, Florida • Park Ridge, Illinois + 3 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130450" }, { "nct_id": "NCT05681351", "title": "CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Hypertriglyceridemia" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 885, "start_date": "2022-12-13", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 65, "location_summary": "Los Angeles, California • San Diego, California • Tarzana, California + 53 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Greenacres City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05681351" }, { "nct_id": "NCT05185843", "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-02-25", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 4, "location_summary": "Huntington Beach, California • Boca Raton, Florida • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05185843" }, { "nct_id": "NCT05355402", "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertriglyceridemia", "Atherosclerotic Cardiovascular Disease", "Severe Hypertriglyceridemia" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2022-05-09", "completion_date": "2023-12-21", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 21, "location_summary": "Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more", "locations": [ { "city": "Lincoln", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05355402" }, { "nct_id": "NCT05579860", "title": "A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 104, "start_date": "2022-10-05", "completion_date": "2023-05-22", "has_results": false, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-09-05T02:46:20.255Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579860" } ] }